Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin

International Journal of Pharmaceutics

Volumn 271, Issue 1-2, 2004, Pages 1-4

  Panchagnula, Ramesh ^a   Agrawal, Shrutidevi ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Bioavailability; Bioequivalence; Fixed dose combination; Rifampicin; Tuberculosis

Indexed keywords

RIFAMPICIN;

BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG QUALITY; DRUG RESEARCH; PRIORITY JOURNAL; REVIEW;

EID: 1142285519     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2003.11.031     Document Type: Note

References (7)

1. Agrawal, S., 2003. Biopharmaceutics and pharmacokinetics of rifampicin: implications in performance and evaluation of anti-tuberculosis fixed dose combination formulations. Ph.D. Thesis, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, India.
2. Blomberg, B., Evans, P., Phanouvong, S., Nunn, P., 2002. Informal consultation on 4-drug fixed dose combinations (4FDCs) compliant with the WHO model list of essential drugs, 15-17 August 2001. World Health Organization, Geneva, WHO/CDS/TB/2002.299.
3. Blomberg B., Spinaci S., Fourie B., Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull. WHO. 79:2001;61-79.
4. Fourie, B., Pillai, G., McIlleron, H., Smith, P., Panchagnula, R., Ellard, G., 1999. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to single drug reference preparations administered in loose combination (Model Protocol). World Health Organization, WHO/CDS/TB/99.274.
5. Fox W., Ellard G.A., Mitchison D.A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units 1946-1986 with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3:1999;S231-S279.
6. Laing, R., Fourie, B., Ellard, G., Sesay, M., Spinaci, S., Blomberg, B., Bryant, D., 1999. Fixed-dose combination tablets for the treatment of tuberculosis. Report of an informal meeting held in Geneva, Tuesday, 27 April 1999. World Health Organization, Geneva, WHO/CDS/CPC/TB/99.267.
7. Panchagnula R., Agrawal S., Kaul C.L. Fixed dose combinations in the treatment of tuberculosis. Ind. J. Pharm. Sci. 63:2001;1-9.